Maria Salling Eghøj1, Torben Lykke Sørensen. 1. Department of Ophthalmology, Copenhagen University Hospital Roskilde, Køgevej 7-13, DK-4000 Roskilde, Denmark. sallingmus@hotmail.com
Abstract
AIM: To determine whether tachyphylaxis occurs during treatment with ranibizumab (Lucentis, Genentech, Inc., South San Francisco, California, USA) for exudative age-related macular degeneration (AMD). DESIGN: Retrospective review of cases. PARTICIPANTS: The treatment results of 1076 eyes (976 patients) treated with ranibizumab for exudative AMD was evaluated to identify patients with a potential tachyphylactic response. The participants had to have a minimum of 12 months follow-up. METHODS: Tachyphylaxis was defined as a lack of response to the drug at the time of reactivation of choroidal neovascularisation (CNV) in patients who had responded to the initial treatment. The authors considered it a lack of response to ranibizumab if a decrease in vision and an increase in central retinal thickness (CRT) were observed despite repeated injections. Hence a stabilisation in vision and/or stabilisation in CRT during treatment were not considered tachyphylaxis, and other unfavourable responses such as a tear in the retinal pigment epithelium and therefore a decrease in vision during treatment were also not considered as tachyphylaxis. Every patient in this cohort who has had an injection-free interval after primary inactivation of CNV and who has received retreatment at a later stage was identified. In this population, those cases that did not respond to retreatment (tachyphylaxis) were identified and characterised. MAIN OUTCOME MEASURES: Number of patients who developed tachyphylaxis after treatment with ranibizumab. RESULTS: 20 patients (2%) developed tachyphylaxis during their treatment. CONCLUSION: Tachyphylaxis can occur during the treatment of exudative AMD with ranibizumab. The precise mechanism for the development of tachyphylaxis is unclear. Both local and systemic factors might be involved.
AIM: To determine whether tachyphylaxis occurs during treatment with ranibizumab (Lucentis, Genentech, Inc., South San Francisco, California, USA) for exudative age-related macular degeneration (AMD). DESIGN: Retrospective review of cases. PARTICIPANTS: The treatment results of 1076 eyes (976 patients) treated with ranibizumab for exudative AMD was evaluated to identify patients with a potential tachyphylactic response. The participants had to have a minimum of 12 months follow-up. METHODS: Tachyphylaxis was defined as a lack of response to the drug at the time of reactivation of choroidal neovascularisation (CNV) in patients who had responded to the initial treatment. The authors considered it a lack of response to ranibizumab if a decrease in vision and an increase in central retinal thickness (CRT) were observed despite repeated injections. Hence a stabilisation in vision and/or stabilisation in CRT during treatment were not considered tachyphylaxis, and other unfavourable responses such as a tear in the retinal pigment epithelium and therefore a decrease in vision during treatment were also not considered as tachyphylaxis. Every patient in this cohort who has had an injection-free interval after primary inactivation of CNV and who has received retreatment at a later stage was identified. In this population, those cases that did not respond to retreatment (tachyphylaxis) were identified and characterised. MAIN OUTCOME MEASURES: Number of patients who developed tachyphylaxis after treatment with ranibizumab. RESULTS: 20 patients (2%) developed tachyphylaxis during their treatment. CONCLUSION: Tachyphylaxis can occur during the treatment of exudative AMD with ranibizumab. The precise mechanism for the development of tachyphylaxis is unclear. Both local and systemic factors might be involved.
Authors: Haiyan Wang; Giulio Barteselli; William R Freeman; Su Na Lee; Jay Chhablani; Sharif El-Emam; Lingyun Cheng Journal: Int J Ophthalmol Date: 2013-10-18 Impact factor: 1.779